Weight-loss drug developer Metsera raises $275 million in US IPO
Jan 31, 2025 · Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners …
OFF
Weight-loss Drug Developer Metsera Raises $275 Million In US IPO
2 weeks from now
Jan 31, 2025 · Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners …
reuters.com
OFF
Metsera’s IPO Raises $275M To Show How Its Obesity Drugs Can …
2 weeks from now
5 days ago · Metsera initially planned to offer more than 17.1 million shares priced in the range of $15 to $17 each, which would have raised $275 million at the pricing midpoint.
medcitynews.com
OFF
Obesity-drug Maker Metsera Posts Largest Gain As IPOs
2 weeks from now
Jan 31, 2025 · New York-based Metsera priced 15.28 million shares at $18 apiece to raise $275 million as the largest of the IPOs pricing for Friday secondary-market debuts terms of dollar …
morningstar.com
OFF
Weight-loss Drug Developer Metsera Raises $275 Million In US IPO
2 weeks from now
Jan 31, 2025 · Bengaluru: Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH …
indiatimes.com
OFF
Metsera, Inc. Prices Initial Public Offering At $18.00 Per Share ...
2 weeks from now
Jan 31, 2025 · Metsera, Inc. prices its IPO at $18 per share, raising approximately $275 million to fund obesity treatments. Quiver AI Summary. Metsera, Inc., a clinical-stage biotechnology …
nasdaq.com
OFF
Metsera, Inc. (MTSR) Stock Price, Quote & News - Stock Analysis
2 weeks from now
3 days ago · Weight-loss drug developer Metsera raises $275 million in US IPO. Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per …
stockanalysis.com
OFF
Weight-loss Drug Developer Metsera Targets Up To $1.78 Billion ...
2 weeks from now
Jan 27, 2025 · Metsera seeks to raise up to $292.2 million in US IPO Venture capital firm ARCH Ventures founded Metsera in 2022 Jan 27 (Reuters) - Metsera, which is developing weight …
reuters.com
OFF
Metsera Readies $275 Million IPO For Obesity Treatments
2 weeks from now
Jan 28, 2025 · Metsera intends to raise $275 million in gross proceeds from an IPO of its common stock, offering approximately 17.19 million shares at a proposed midpoint price of $16.00 per …
seekingalpha.com
OFF
Metsera Inc. | IPOScoop
2 weeks from now
Jan 30, 2025 · Note: Net loss and no product revenue are for the 12 months that ended Sept. 30, 2024. (Note: Metsera Inc. priced its IPO at $18.00 – $1.00 above the top of its $15.00-to …
iposcoop.com
OFF
Weight-loss Drug Developer Metsera Reveals Wider Loss In US IPO …
2 weeks from now
Jan 10, 2025 · Metsera reports $156.26 million loss in first nine months of 2024 Proceeds from IPO to fund MET-097i clinical trials Weight-loss drug market projected to reach $150 billion by …
reuters.com
OFF
Metsera Secures $275 Million In IPO As Weight-Loss Drug Market …
2 weeks from now
The company sold 15.28 million shares, surpassing its original plan to market 17.19 million shares priced between $15 and $17. With a pre-IPO valuation of $1.8 billion, Metsera has positioned …
wallstreetconservative.com
OFF
Weight-loss Drug Developer Metsera Seeks Up To $1.78 Billion
2 weeks from now
New York City-based Metsera seeks to raise up to $292.2 million by offering 17.19 million shares, priced between $15 and $17 each. The weight-loss drug market, estimated to be worth about …
msn.com
OFF
Obesity Drug Developer Metsera Sets Terms For $275M IPO
2 weeks from now
Jan 27, 2025 · In a recent SEC filing, Metsera said it was looking to offer 17.2M shares priced between $15 and $17, which would raise around $275M if priced at the midpoint. Underwriters …
seekingalpha.com
OFF
Obesity Biotech Metsera Sets Terms For $275 Million IPO
2 weeks from now
Jan 27, 2025 · The New York, NY-based company plans to raise $275 million by offering 17.2 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Metsera …
renaissancecapital.com
OFF
Weight-Loss Drug Developer Metsera Targets Up To $1.78 Billion ...
2 weeks from now
Jan 27, 2025 · Weight-Loss Drug Developer Metsera Targets up to $1.78 Billion Valuation in US IPO. By Reuters | Jan. 27, 2025 ... New York City-based Metsera is aiming to raise up to …
usnews.com
OFF
Weight-loss Drug Developer Metsera Targets Up To $1.78 Billion ...
2 weeks from now
Jan 27, 2025 · Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO. ... New York City-based Metsera is aiming to raise up to $292.2 million by offering 17.19 …
investing.com
OFF
Weight-Loss Drug Developer Metsera Reveals Wider Loss In US …
2 weeks from now
Jan 10, 2025 · Metsera, founded in 2022 by venture capital firm ARCH Venture and investment firm Population Health Partners, revealed a net loss of $156.26 million in the first nine months …
usnews.com
OFF
Weight-loss Drug Developer Metsera Raises $275 Million In US IPO
2 weeks from now
Jan 31, 2025 · Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners …
tradingview.com
OFF
Metsera Raises $275M In IPO To Advance GLP-1 Weight Loss Drug …
2 weeks from now
Jan 27, 2025 · Metsera priced its initial public offering (IPO) at $18.00 per share, raising approximately $275 million10.. The company offered 15,277,778 shares of common stock and …
talk.bio
OFF
Weight-loss Drug Developer Metsera Targets Up To $1.78 Billion
2 weeks from now
(Reuters) -Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is aiming for a valuation of up to $1.78 billion in its …
msn.com
OFF
Metsera’s IPO Raises $275M To Show How Its Obesity Drugs Can …
2 weeks from now
6 days ago · Investors showed appetite for Metsera’s IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. ... Metsera’s IPO Raises …
ramaonhealthcare.com
OFF
GLP-1RA Developer Metsera Targets $289m IPO
2 weeks from now
Jan 28, 2025 · US-based Metsera has set its sights on a $289m public listing as the weight loss drug developer becomes one of the early biotechs to venture into the thawing IPO landscape …
pharmaceutical-technology.com
OFF
Buy Metsera Inc (MTSR) Stock - Public.com
2 weeks from now
Jan 31, 2025 · U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs ... Reuters • 01/31/25. Weight-loss drug developer Metsera raises $275 million in US IPO. …
public.com
OFF
Weight-loss Drug Developer Metsera Raises $275 Million In US IPO
2 weeks from now
Jan 31, 2025 · Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners …
tradingview.com
FAQs about Weight-loss drug developer Metsera raises $275 million in US IPO Coupon?
Why did metsera raise $275 million?
Did metsera lose its IPO?
How much does metsera's IPO cost?
Did metsera lose a weight-loss drug?
How much money did metsera raise in 2024?
What happened to metsera?
Install CouponFollow Extension on Chrome
Install the CouponFollow extension to search for discount codes when shopping the fastest!
Install CouponFollow Chrome Extension
Listing Store by Characters
